Investment Analysts’ Weekly Ratings Changes for Dyne Therapeutics (DYN)

Several analysts have recently updated their ratings and price targets for Dyne Therapeutics (NASDAQ: DYN):

• 8/1/2026 – Dyne Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 7/31/2026 – Dyne Therapeutics had its price target lowered by Morgan Stanley from $47.00 to $45.00. They now have an “overweight” rating on the stock.
• 7/30/2026 – Dyne Therapeutics had its price target raised by Royal Bank Of Canada from $30.00 to $35.00. They now have an “outperform” rating on the stock.
• 7/23/2026 – Dyne Therapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 7/17/2026 – Dyne Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/6/2026 – Dyne Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 6/26/2026 – Dyne Therapeutics is now covered by TD Cowen. They set a “buy” rating on the stock.
• 6/20/2026 – Dyne Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.

Insider Transactions at Dyne Therapeutics

In related news, Director Brian S. Posner acquired 2,000 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The shares were acquired at an average cost of $16.94 per share, for a total transaction of $33,880.00. Following the completion of the acquisition, the director directly owned 24,500 shares in the company, valued at approximately $415,030. The trade was a 8.89% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Erick Lucera sold 2,362 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total transaction of $48,113.94. Following the completion of the sale, the chief financial officer directly owned 121,563 shares in the company, valued at $2,476,238.31. This represents a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders purchased 9,000 shares of company stock valued at $156,800 and sold 1,552,268 shares valued at $34,264,958. 9.46% of the stock is owned by insiders.

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.